CiteFacts · FDA Drug Shortages · FDA source
Dextrose Monohydrate 50% Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) | Available | 08/18/2026 |
| Hospira, Inc., a Pfizer Company | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) | Limited Availability | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34) | Not stated | 11/07/2025 |
Source facts
Grouped generic ingredient: Dextrose Monohydrate 50% Injection · 5 package records · Latest FDA row update: 11/07/2025
Therapeutic categories: Endocrinology/Metabolism, Gastroenterology, Pediatric
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.